Journal of dermato-oncology最新文献

SIRT6 promotes a mesenchymal, invasive phenotype in melanoma. SIRT6促进黑色素瘤的间质侵袭性表型。

Journal of dermato-oncology Pub Date : 2026-01-01 Epub Date: 2026-07-12 DOI: 10.1080/29944376.2026.2700162

Liz M Garcia-Peterson, Amelia M Lemkuil, Mary A Ndiaye, Nihal Ahmad, Gagan Chhabra

{"title":"SIRT6 promotes a mesenchymal, invasive phenotype in melanoma.","authors":"Liz M Garcia-Peterson, Amelia M Lemkuil, Mary A Ndiaye, Nihal Ahmad, Gagan Chhabra","doi":"10.1080/29944376.2026.2700162","DOIUrl":"10.1080/29944376.2026.2700162","url":null,"abstract":"Melanoma is a highly aggressive cutaneous malignancy with significant metastatic potential, posing ongoing challenges in elucidating the molecular mechanisms driving its progression. Epithelial-mesenchymal transition (EMT) is a key process that enhances cancer cell migration and invasion, facilitating metastatic dissemination. Sirtuin 6 (SIRT6), a NAD+-dependent enzyme, has been reported to either promote or suppress EMT in a context-dependent manner; however, its function in melanoma remains poorly defined. We previously showed that SIRT6 is overexpressed in melanoma tissues and cells, where it contributes to tumor growth via an autophagy-dependent mechanism. In this study, we further investigated the role of SIRT6 in EMT using melanoma cells with stable overexpression or shRNA-mediated knockdown. Overexpression of SIRT6 enhanced cell proliferation and clonogenic survival and was associated with increased expression of mesenchymal markers and EMT-associated transcription factors. Conversely, SIRT6 knockdown significantly reduced the expression of these genes. Functionally, SIRT6 depletion markedly impaired cell migration and invasion, as demonstrated by wound-healing and Matrigel invasion assays. Collectively, these findings identify SIRT6 as a promoter of an invasive, mesenchymal phenotype in melanoma. Our results support a potential oncogenic role for SIRT6 and highlight its inhibition as a promising therapeutic strategy to limit melanoma progression and metastasis.","PeriodicalId":521256,"journal":{"name":"Journal of dermato-oncology","volume":"2 1","pages":"2700162"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13645373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149140334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanistic and preclinical evaluation of SIRT3 as a therapeutic target in melanoma. SIRT3作为黑色素瘤治疗靶点的机制和临床前评估。

Journal of dermato-oncology Pub Date : 2026-01-01 Epub Date: 2026-04-14 DOI: 10.1080/29944376.2026.2656032

Karla B Anaya Aldrete, Mary A Ndiaye, Glorimar Guzmán-Pérez, Gabriella R Zaemisch, Chandra K Singh, Gagan Chhabra, Nihal Ahmad

{"title":"Mechanistic and preclinical evaluation of SIRT3 as a therapeutic target in melanoma.","authors":"Karla B Anaya Aldrete, Mary A Ndiaye, Glorimar Guzmán-Pérez, Gabriella R Zaemisch, Chandra K Singh, Gagan Chhabra, Nihal Ahmad","doi":"10.1080/29944376.2026.2656032","DOIUrl":"10.1080/29944376.2026.2656032","url":null,"abstract":"Despite advances in targeted inhibitors and immunotherapies, melanoma remains one of the deadliest skin cancers due to high metastatic potential and resistance to current therapies. This underscores a critical need for new, mechanism-based treatment strategies. Sirtuins, a family of class III histone deacetylases, have been implicated by our lab and others in numerous cellular functions, diseases, and cancers including melanoma. Here, we sought to extend our findings on the pro-proliferative role of SIRT3 by: (i) defining downstream mechanisms using PCR array and NanoString gene-expression profiling on CRISPR/Cas9-mediated SIRT3 knockout (KO) in melanoma cells; (ii) assessing effects of siRNA against SIRT3 in patient-derived xenograft (PDX) and BrafV600E/PtenNULL melanoma models; and (iii) evaluating efficacy of SIRT3 inhibitor 4'-Bromo-resveratrol (4'-BR) in PDXes. SIRT3 KO significantly reduced growth and colony formation in A375 and G361 melanoma cells. PCR array and NanoString analysis revealed modulation of key cancer-related signaling molecules. In vivo, siRNA-mediated SIRT3 inhibition in melanoma PDXes and BrafV600E/PtenNULL mice trended toward reduced tumor growth. However, dual SIRT1/SIRT3 inhibition with 4'-BR (50 mg/kg, ip, 2x/week) significantly decreased tumor volume and weight in melanoma PDXes. Overall, our data suggests that targeting SIRT1 and SIRT3 together could offer greater therapeutic benefit and should be validated and optimized.","PeriodicalId":521256,"journal":{"name":"Journal of dermato-oncology","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13178468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147966753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blue light and ultraviolet radiation: comparative biophysical properties and their roles in skin carcinogenesis and photoaging. 蓝光和紫外线辐射：比较生物物理特性及其在皮肤致癌和光老化中的作用。

Journal of dermato-oncology Pub Date : 2026-01-01 Epub Date: 2025-12-19 DOI: 10.1080/29944376.2025.2595383

Robert L McKay, Shiyong Wu

引用次数: 0

Liquid Biopsy for Cutaneous Melanoma: Opportunities and Challenges in Detecting and Characterizing Circulating Tumor Cells. 皮肤黑色素瘤液体活检：检测和表征循环肿瘤细胞的机遇和挑战。

Journal of dermato-oncology Pub Date : 2025-01-01 Epub Date: 2025-11-10 DOI: 10.1080/29944376.2025.2578127

Weizheng Wang, Rylee Rickett, Sireesh Teertam, Sundaram Gunasekaran, Vijayasaradhi Setaluri

引用次数: 0